Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Dry Eye > TRPM8 pathway emerges as key target for dry eye therapy
  • Dry Eye

TRPM8 pathway emerges as key target for dry eye therapy

Ophthalmology 360

A new review highlights the critical role of the lacrimal functional unit (LFU) in maintaining ocular surface health through tightly regulated tear secretion. At the center of this system are corneal sensory nerves, which detect environmental changes via transient receptor potential (TRP) ion channels.

Among these channels, TRP melastatin 8 (TRPM8) stands out as a central regulator of basal tear production. Activated by slight temperature drops and increased tear film osmolarity from evaporative cooling, TRPM8 stimulates the LFU to boost tear secretion.

Preclinical and early clinical data highlight the essential role of TRPM8 in ocular homeostasis, suggesting that enhancing this pathway could pave the way for new therapies for dry eye disease. Researchers propose that TRPM8 agonists, by directly amplifying this natural tear-promoting mechanism, may provide a promising alternative for patients with limited treatment options.

Learn more.

Reference

Gallar J, Pflugfelder S, Galor A, et al. Corneal sensory nerve regulation of tear production through stimulation of transient receptor potential melastatin 8 (TRPM8) channel: A potential new approach for treating dry eye disease. Ocul Surf. 2025 Jul 18;38:142-154. doi: 10.1016/j.jtos.2025.07.003. Epub ahead of print. PMID: 40685077.

Share

Related Content

  • Dry Eye

Preservative-free lubricants linked to improved dry eye symptoms in real-world study

  • Dry Eye

Spotlight on LACRIFILL®

  • Conference Roundup

If your patient has recurrent chalazia, consider co-occurring Demodex blepharitis

  • Conference Roundup

Ocular staining and dry mouth may help identify Sjögren’s-related dry eye

  • Conference Roundup

Daily vaping associated with increased risk of ocular surface disease

  • Conference Roundup

Nearly half of eye care providers show Demodex infestation, with severity increasing over time in practice

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon